Rui Gong
gongr@wh.iov.cn
Chinese, English
Hubei
University of Chinese Academy of Sciences
Medical School
  • 2002-09--2007-06 PhD: Wuhan University
  • 1998-09--2002-06 Bachelor's: Wuhan University
  • 2012-09~Present - Chinese Academy of Sciences Wuhan Institute of Virology - Researcher
  • 2007-09~2012-08 - National Institutes of Health, USA - Postdoctoral Fellow
  • Federal Technology Transfer Award (2012): Detail
  • Federal Technology Transfer Award (2011): Detail
Antibody Engineering
Biopharmaceuticals
Antiviral and Tumor Antibodies
Virus-Host Interactions
  • Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study, Wang, Hao, Gan, Mengze, Wu, Bihao, Zeng, Rui, Wang, Zhen, Xu, Jun, Li, Jia, Zhang, Yandi, Cao, Jinge, Chen, Li, Di, Dongsheng, Peng, Siyuan, Lei, Jinfeng, Zhao, Yingying, Song, Xuemei, Yuan, Tingting, Zhou, Tingting, Liu, Qian, Yi, Jing, Wang, Xi, Cai, Hao, Lei, Yanshou, Wen, Yuying, Li, Wenhui, Chen, Qinlin, Wang, Yufei, Long, Pinpin, Yuan, Yu, Wang, Chaolong, Pan, An, Wang, Qi, Gong, Rui, Fan, Xionglin, Wu, Tangchun, Liu, Li, 2023
  • An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response, Li Chen, Haiwei Zhang, Moxuan Li, Bihao Wu, Zhe Zhang, Rui Gong, 2022
  • Immunotherapy targeting mesothelin in acute myeloid leukemia, Wang, Qingguang, Gong, Rui, 2022
  • A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern, Zhang, RuYan, Yin, XuGuang, Zhou, ShiHao, Zhang, HaiWei, Lu, Jie, He, ChenBin, Wang, Jian, Wen, Yu, Li, YuTing, Liu, YanLing, Feng, RanRan, Ding, Dong, Wei, HuaWei, Gong, Rui, Yang, GuangFu, Guo, Jun, 2022
  • A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery, Zhang, Xinghai, Zhang, Huajun, Li, Tingting, Chen, Shaohong, Luo, Feiyang, Zhou, Junhui, Zheng, Peiyi, Song, Shuyi, Wu, Yan, Jin, Tengchuan, Tang, Ni, Jin, Aishun, Yang, Chengyong, Cheng, Guofeng, Gong, Rui, Chiu, Sandra, Huang, Ailong, 2022
  • SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma, Chen, Li, Yue, Junqing, Zhang, Shengding, Bai, Wenxue, Qin, Lu, Zhang, Cong, Wu, Bihao, Li, Moxuan, Xu, Shuyun, Jiang, Qing, Yang, Lin, Xu, Qingxiu, Zhu, Rongfei, Xie, Min, Gong, Rui, 2022
  • Self-Adjuvanting Lipoprotein Conjugate alpha GalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern, Wang, Jian, Wen, Yu, Zhou, ShiHao, Zhang, HaiWei, Peng, XiaoQian, Zhang, RuYan, Yin, XuGuang, Qiu, Hong, Gong, Rui, Yang, GuangFu, Guo, Jun, 2022
  • Structural basis of nanobodies neutralizing SARS-CoV-2 variants, Shi, Zhenzhong, Li, Xiyang, Wang, Lu, Sun, Zengchao, Zhang, Haiwei, Chen, Xiaochen, Cui, Qianqian, Qiao, Huarui, Lan, Zhongyun, Zhang, Xin, Li, Xianheng, Li, Lingyun, Xu, Jianfeng, Gong, Rui, Fan, Chengpeng, Geng, Yong, 2022
  • RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern, Zhou, ShiHao, Zhang, RuYan, Zhang, HaiWei, Liu, YanLing, Wen, Yu, Wang, Jian, Li, YuTing, You, ZiWei, Yin, XuGuang, Qiu, Hong, Gong, Rui, Yang, GuangFu, Guo, Jun, 2022
  • Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection, Hao Wang, Yu Yuan, Mingzhong Xiao, Li Chen, Youyun Zhao, Haiwei Zhang, Pinpin Long, Yana Zhou, Xi Xu, Yanshou Lei, Bihao Wu, Tingyue Diao, Hao Cai, Li Liu, Zuoyu Shao, Jingzhi Wang, Yansen Bai, Kai Wang, Miao Peng, Linlin Liu, Shi Han, Fanghua Mei, Kun Cai, Yake Lei, An Pan, Chaolong Wang, Rui Gong, Xiaodong Li, Tangchun Wu, 2021
  • IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability, Yuan Zhang, Yanqiu Wei, Yunlong Li, Xuan Wang, Yang Liu, Deyu Tian, Xiaojuan Jia, Rui Gong, Wenjun Liu, Limin Yang, 2021
  • Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein, Xun, Guangjin, Song, Xingpan, Hu, Jie, Zhang, Haiwei, Liu, Lan, Zhang, Zhe, Gong, Rui, 2021
  • Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics, Zhao, Shaojuan, Zhang, Huajun, Yang, Xinglou, Zhang, Haiwei, Chen, Ying, Zhan, Yancheng, Zhang, Xiaoqing, Jiang, Rendi, Liu, Meiqin, Liu, Lan, Chen, Li, Tang, Wei, Peng, Cheng, Gao, Xiaoxiao, Zhang, Zhe, Shi, Zhengli, Gong, Rui, 2021
  • Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus, Wang, Rui, Zhang, Haiwei, Peng, Cheng, Shi, Jian, Zhang, Huajun, Gong, Rui, 2021
  • A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential, Gai, Junwei, Ma, Linlin, Li, Guanghui, Zhu, Min, Qiao, Peng, Li, Xiaofei, Zhang, Haiwei, Zhang, Yanmin, Chen, Yadong, Ji, Weiwei, Zhang, Hao, Cao, Huanhuan, Li, Xionghui, Gong, Rui, Wan, Yakun, 2021
  • Vaccination with Consensus H7 Elicits Broadly Reactive and Protective Antibodies against Eurasian and North American Lineage H7 Viruses, Fadlallah, Gendeal M, Ma, Fuying, Zhang, Zherui, Hao, Mengchan, Hu, Juefu, Li, Mingxin, Liu, Haizhou, Liang, Biling, Yao, Yanfeng, Gong, Rui, Zhang, Bo, Liu, Di, Chen, Jianjun, 2020
  • Immunoglobulin fragment F(ab ')(2) against RBD potently neutralizes SARS-CoV-2 in vitro, Pan, Xiaoyan, Zhou, Pengfei, Fan, Tiejiong, Wu, Yan, Zhang, Jing, Shi, Xiaoyue, Shang, Weijuan, Fang, Lijuan, Jiang, Xiaming, Shi, Jian, Sun, Yuan, Zhao, Shaojuan, Gong, Rui, Chen, Ze, Xiao, Gengfu, 2020
  • An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding, Cao, Guangcan, Gao, Xinyu, Zhan, Yancheng, Wang, Qingguang, Zhang, Zhe, Dimitrov, Dimiter S, Gong, Rui, 2020
  • 沙粒病毒科烈性病毒研究领域的文献计量和知识图谱分析, 马丽丽, 龚睿, 吴跃伟, 刘欢, 2020
  • Optimization of the C-Terminus of an Autonomous Human IgG1 CH2 Domain for Stability and Aggregation Resistance, Gao, Xinyu, Conard, Alex, Yang, Chunpeng, Zhan, Yancheng, Zeng, Fang, Shi, Jian, Lo, Wei, Dimitrov, Dimiter S, Gong, Rui, 2019
  • Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure, Chunpeng Yang, Rui Gong, Natalia de Val, 2019
  • A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans, Li, Mingxin, Chen, Li, Wang, Qingguang, Hao, Mengchan, Zhang, Xiaoqing, Liu, Linlin, Yu, Xiao, Yang, Chunpeng, Xu, Junqiang, Chen, Jianjun, Gong, Rui, 2019
  • Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure, Yang, Chunpeng, Gong, Rui, de Val, Natalia, 2019
  • Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design, Yang, Chunpeng, Zeng, Fang, Gao, Xinyu, Zhao, Shaojuan, Li, Xuan, Liu, Sheng, Li, Na, Deng, Chenglin, Zhang, Bo, Gong, Rui, 2019
  • Characterization of two engineered dimeric Zika virus envelope proteins as immunogen for neutralizing antibody selection and vaccine design, Rui Gong, 2019
  • Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment, Zeng, Fang, Yang, Chunpeng, Gao, Xinyu, Li, Xuan, Zhang, Zhe, Gong, Rui, 2018
  • Antibody Fc Engineering: Towards Better Therapeutics, Lei, Cheng, Gong, Rui, Ying, Tianlei, 2018
  • Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics, Yang, Chunpeng, Gao, Xinyu, Gong, Rui, 2018
  • Screening and expressing HIV-1 specific antibody fragments in Saccharomyces cerevisiae, Wang, Ying, Shan, Yaming, Gao, Xinyu, Gong, Rui, Zheng, Jun, Zhang, Xiaohua Douglas, Zhao, Qi, 2018
  • 克里米亚-刚果出血热病毒新型治疗性抗体研制展望, 刘欢, 张怀东, 陈晓晖, 龚睿, 2018
  • Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus, Sun, Yaping, Zhang, Huaidong, Shi, Jian, Zhang, Zhe, Gong, Rui, 2017
  • Engineered antibody CH2 domains binding to nucle
Antibody Engineering Biopharmaceuticals Antiviral Tumor Virus Host Interactions Immunology Microbiology

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.